_256_384.jpg)
News | June 19, 2024
Cipla EU to invest an additional € 3 million in Ethris
Cipla had earlier invested € 15 million in Ethris in 2022
Cipla had earlier invested € 15 million in Ethris in 2022
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
This strategic decision will unlock significant value for our scientific and industrial products business
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Subscribe To Our Newsletter & Stay Updated
